As we move toward the more advanced pain pharmacology, we encounter medications that do not merely “numb” pain or “strengthen” inhibition, but instead target the fundamental physiological changes that occur when pain becomes chronic. NMDA Antagonists (like Ketamine) and Membrane Stabilizers (like intravenous Lidocaine) are designed to disrupt the pathological “loop” of central sensitization. These are often used for refractory neuropathic pain, Complex Regional Pain Syndrome (CRPS), and opioid-induced hyperalgesia.

---

1. NMDA Antagonists: The Systemic “Reset”

The N-methyl-D-aspartate (NMDA) receptor is the “holy grail” of chronic pain neurobiology. The NMDA receptor is a glutamate-gated ion channel that remains dormant under normal conditions. In chronic pain, however, it becomes the primary engine for Long-Term Potentiation (LTP) and “Wind-up.”

I. Ketamine: The Prototype

Originally developed as a “dissociative” anesthetic, Ketamine has become a mainstay in chronic pain management at “sub-anesthetic” doses.

• Mechanism of Action: Ketamine is a non-competitive antagonist of the NMDA receptor. It physically “plugs” the channel, preventing the influx of calcium and effectively “re-plugging” the magnesium hole that was lost during sensitization.
• Beyond the NMDA: Ketamine also has mild activity at Mu-opioid receptors, interacts with the descending inhibitory monoaminergic system, and reduces pro-inflammatory cytokines in the CNS.
• Clinical Indications:
  • Refractory CRPS: High-dose, multi-day infusions are used to “reset” the central nervous system.
  • Opioid-Induced Hyperalgesia (OIH): Ketamine can reverse the sensitization caused by chronic opioid use.
  • Palliative Care: Used for “total pain” that is unresponsive to high-dose opioids.

II. Side Effects and “The Dissociative State”

The primary barrier to Ketamine use is its unique side-effect profile, which is heavily tested on boards:

• Psychotomimetic Effects: Hallucinations, vivid dreams, and “out-of-body” experiences (dissociation). These are often managed by co-administering Benzodiazepines or Midazolam.
• Sympathetic Surge: It causes a release of catecholamines, leading to Tachycardia and Hypertension. It should be used with caution in patients with uncontrolled ischemic heart disease.
• Cystitis: Chronic use (often seen in recreational abuse) can lead to severe, hemorrhagic “Ketamine Cystitis” of the bladder.

III. Memantine and Dextromethorphan

• Memantine (Namenda): An oral, low-affinity NMDA antagonist. While primarily used for Alzheimer’s, it is sometimes used off-label in pain clinics for its “mild” reset effect with fewer side effects than Ketamine.
• Dextromethorphan: A common antitussive that has weak NMDA-antagonist properties. On the boards, it is sometimes mentioned as an adjuvant to prevent opioid tolerance.

---

2. Membrane Stabilizers: Targeting the “Firing” of the Nerve

While NMDA antagonists target the synapse, membrane stabilizers target the Action Potential itself. In damaged nerves, sodium channels (Na+) become upregulated and begin to fire spontaneously—even without a stimulus.

I. Intravenous Lidocaine Infusions

Lidocaine is a Class 1b antiarrhythmic that acts as a potent sodium channel blocker.

• Mechanism: It binds to voltage-gated sodium channels, particularly the Nav 1.7 and Nav 1.8 subtypes found on nociceptors. It reduces the “ectopic firing” of injured nerves and has a potent systemic anti-inflammatory effect.
• Indications: Used as a trial for patients with refractory neuropathic pain or as a diagnostic indicator to see if the patient might respond to oral sodium channel blockers like Mexiletine.
• Board Pearl: LAST (Local Anesthetic Systemic Toxicity). Even when used for pain, you must know the signs of toxicity: metallic taste, perioral numbness, tinnitus, and the progression to seizures and cardiovascular collapse. The treatment is 20% Intralipid.

II. Mexiletine

Mexiletine is essentially an “oral version” of Lidocaine.

• Use: It is used to maintain the analgesic effect after a successful Lidocaine infusion.
• Clinical Monitoring: Because it is an antiarrhythmic, a baseline EKG is mandatory to check for heart block or prolonged Q-T intervals.

III. Journavx (Suzetrigine): The New Frontier of Peripheral Selection

Approved by the FDA in early 2025 as a first-in-class non-opioid analgesic, Journavx (suzetrigine) represents a paradigm shift by targeting pain signals before they reach the spinal cord and brain.

• Mechanism of Action: Unlike lidocaine, Journavx is a highly selective Nav 1.8 voltage-gated sodium channel inhibitor. Because the Nav 1.8 subtype is expressed almost exclusively on peripheral nociceptive sensory neurons (such as dorsal root ganglion neurons), it prevents the generation and conduction of action potentials directly at the source of pain.
• The Board Distinction: Because it avoids blocking sodium channels in cardiac tissue and the central nervous system, Journavx provides potent analgesia for moderate-to-severe acute pain without the risks of sedation, addiction, respiratory depression, or LAST. It is a non-controlled substance.
• Dosing & Administration: Initiated with a loading dose of 100 mg (two 50 mg tablets) taken on an empty stomach (1 hour before or 2 hours after a meal) to guarantee rapid onset. Maintenance dosing is 50 mg orally every 12 hours (with or without food).
• Drug Interactions & Contraindications: Heavily metabolized via the CYP3A4 path. It is strictly contraindicated with strong CYP3A inhibitors and patients must avoid grapefruit products. Additionally, it acts as a CYP3A inducer, which can decrease the efficacy of certain hormonal contraceptives; female patients require a non-hormonal backup method during and for 28 days following therapy.

---

3. Opioid-Induced Hyperalgesia: The Link to NMDA

The boards frequently link NMDA antagonists to opioid therapy.

• The Concept: Chronic opioid use activates NMDA receptors via a protein called Protein Kinase C (PKC). This activation leads to the paradoxical increase in pain (OIH).
• The Solution: Small doses of NMDA antagonists can “prevent” or “reverse” this process, making opioids more effective (or allowing for a successful taper).

---

4. Summary Table for Board Review

Medication	Category	Mechanism	High-Yield Board Fact
Ketamine	NMDA Antagonist	Non-competitive Block	Causes dissociation; raises BP/HR.
Lidocaine (IV)	Membrane Stabilizer	Sodium Channel Blocker	Watch for LAST; Treat with Intralipid.
Mexiletine	Membrane Stabilizer	Sodium Channel Blocker	Oral Lidocaine; Check EKG first.
Memantine	NMDA Antagonist	Low-affinity Block	Used off-label for centralized pain.

---

5. Clinical Integration

In the PM&R setting, these medications are used to “open the window” for functional restoration.

• CRPS Rehab: A patient with CRPS may be unable to tolerate even the touch of a therapist’s hand (allodynia). A Ketamine or Lidocaine infusion can dampen the central and peripheral sensitization enough to allow the patient to engage in Desensitization Therapy and active movement, which are the only long-term “cures” for the condition.
• The “Reset” vs. the “Maintenance”: We emphasize to patients that these are not “cure-all” drugs but tools to break a cycle. The true “membrane stabilizer” is often consistent, low-impact aerobic movement that restores natural descending inhibition.

---

6. High-Yield Board “Fast Facts”

• Nav 1.7: The “high-yield” sodium channel subtype associated with human pain disorders.
• Magnesium: The natural NMDA-channel blocker that is displaced during Wind-up.
• Dissociation: The hallmark side effect of Ketamine (hallucinations, vivid dreams).
• Metallic Taste/Tinnitus: The first signs of Lidocaine toxicity.
• 20% Lipid Emulsion: The “antidote” for local anesthetic systemic toxicity.
• NMDA activation: The reason why increasing opioids sometimes makes pain worse.

---

7. Historical Depth: From Anesthetic to Analgesic

Ketamine was synthesized in 1962 as a safer alternative to Phencyclidine (PCP). It was used extensively in the Vietnam War because it maintained respiratory drive and blood pressure—critical for “field” anesthesia. The discovery of its use in chronic pain came decades later, in the 1990s, as researchers began to uncover the role of the NMDA receptor in “Wind-up.” This journey from the “operating theater” to the “pain clinic” illustrates how our understanding of neurobiology can repurpose old drugs to solve new problems in the management of chronic disability.